# US 2022/0065861 A1 · Patient specific clinical trials and associated methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0065861 A1
- Document ID: US20220065861A1
- Status: Published application
- Kind: A1
- Application number: 16/649,639
- Filed: 2018-09-27
- Published: 2022-03-03
- Earliest claimed: 2017-09-27
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Xiling SHEN; Shiaowen David HSU
- Web page: https://patentgrep.com/patent/US20220065861A1

## CPC

- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5047: {Cells of the immune system}
- G01N 33/5088: {of vertebrates}
- G16H 10/20: for electronic clinical trials or questionnaires
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 30/00: ICT specially adapted for the handling or processing of medical images (computed tomography A61B6/03)
- G16H 30/40: for processing medical images, e.g. editing
- G16H 50/50: for simulation or modelling of medical disorders
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Patient specific clinical trials and associated methods of treatment are disclosed. According to an aspect, a method includes generating a patient specific tumor model. The method also includes testing one or more drugs on the patient specific tumor model. Further, the method includes treating a patient based on the results of the patient specific tumor model tests.

## Claims

### Claim 1

A clinical trial system comprising:
generating a patient specific tumor model from tissue from a patient's tumor;
testing one or more drugs on the patient specific tumor model; and
treating a patient based on the results of the patient specific tumor model tests,
wherein the patient specific tumor model comprises an organoid and the organoid comprises tumor immune, endothelial and mesenchymal cells.

### Claim 2 (depends on 1)

The clinical trial system of claim 1, wherein the patient's tumor is a colorectal cancer tumor.

### Claim 3 (depends on 1)

The clinical trial system of claim 1, further comprising:
entering patient specific information into a computational model; and
treating a patient based on the results of the patient specific tumor model tests and the computational model.

### Claim 4 (depends on 3)

The clinical trial system of claim 3, wherein the patient specific information comprises at least one of biopsy immunohistochemistry (IHC), biopsy sequencing data, biomarkers, diagnostic information, genetic mutations present in the tumor, medical images, histology images, immunohistochemistry images, patient disease progression throughout treatment, and results of patient specific tumor model tests.

### Claim 5 (depends on 1)

The clinical trial system of claim 1, wherein the tested drug comprises oxaliplatin.

### Claim 6 (depends on 1)

The clinical trial system of claim 1, wherein the patient specific tumor model comprises an organoid.

### Claim 7 (depends on 6)

The clinical trial system of claim 6, wherein the model is generated and the one or more drugs are tested within 10 days of acquiring the patient biopsy.

### Claim 8 (depends on 6)

The clinical trial system of claim 6, wherein the model is generated and the one or more drugs are tested within 3 days of acquiring the patient biopsy.

### Claim 9 (depends on 6)

The clinical trial system of claim 6, wherein the organoids are implemented in a 2-D monolayer culture.

### Claim 10 (depends on 6)

The clinical trial system of claim 6, wherein isolated patient blood or T cells are added to the organoid.

### Claim 11 (depends on 6)

The clinical trial system of claim 6, wherein a CRISPR screen with pooled guide RNAs is conducted.

### Claim 12 (depends on 6)

The clinical trial system of claim 6, wherein the organoid is created by obtaining a biopsy of tissue from the patient's tumor; digesting cells from the biopsied tissue; and seeding the cells such that tumor immune, endothelial and mesenchymal cells are included in the organoid.

### Claim 13

A method of creating a patient-derived tumor organoid, the method comprising:
obtaining a biopsy of tissue from a patient's tumor;
digesting cells from the biopsied tissue; and
seeding the cells such that tumor immune, endothelial and mesenchymal cells are included in the organoid.

### Claim at position 14

-23. (canceled)

### Claim 24

An organoid comprising Matrigel, tumor immune, tumor endothelial and tumor mesenchymal cells.

### Claim 25 (depends on 24)

The organoid of claim 24, wherein the tumor is a colorectal cancer tumor

### Claim 26 (depends on 13)

The method of claim 13, wherein the patient's tumor is a colorectal cancer tumor.

### Claim 27 (depends on 13)

The method of claim 13, wherein the organoid further comprises Matrigel.

### Claim 28 (depends on 13)

The method of claim 13, wherein less than 2 mm3 of tissue is digested.

### Claim 29 (depends on 28)

The method of claim 28, wherein the seeding occurs over no more than 7 days.
